What Фуразидин Treats: Main Uses and Benefits

Фуразидин is commonly used to help manage uncomplicated lower urinary tract infections (UTIs), including acute episodes of cystitis (bladder infection) and urethritis. Its application is relevant in conditions involving certain distressing symptoms, where it is commonly used to help address the infectious source within the urinary system. This class of drugs is indicated for treating and preventing these types of infections. The use of this medication may assist in easing the overall symptom load and may support reducing the potential for symptom progression.

Quick Fact: Relief for Acute Discomfort

This treatment is relevant for easing symptoms that create noticeable physiological strain during acute or episodic changes in the urinary tract.

This medication is applied in addressing the distressing group of symptoms associated with active UTIs, which include the pain and burning sensation (dysuria) during urination, along with urinary urgency and frequency. The medication helps ease the symptom burden. It contributes to improved day-to-day comfort and supports maintaining functional stability.

Фуразидин is relevant for conditions involving episodic or fluctuating manifestations, as it is also commonly used to help manage and prevent the recurrence of lower UTIs. This preventative application may assist with maintaining a sense of stability and may help limit the disruptive frequency of repeat symptomatic episodes.

“This medication helps ease the symptom burden and contributes to improved day-to-day comfort.”

Regulatory References

1. NIH MedlinePlus overview of Nitrofurantoin

Eligibility Map: Who Can and Cannot Use Фуразидин

Official regulatory documentation defines eligibility for Фуразидин (Furazidine) based on specific age, physiological, and genetic criteria. Use is contraindicated in several specific populations due to the risk of serious complications.

---

Populations for Whom Use is Contraindicated

• Severe Renal Impairment: Use is absolutely prohibited in patients with severe chronic renal insufficiency (e.g., Creatinine Clearance less than 30 mL/min), anuria, or oliguria, due to the risk of drug accumulation and toxicity.
• Genetic Deficiency: Individuals with Glucose-6-phosphate dehydrogenase (G6PD) deficiency must not use this medicine.
• Hypersensitivity: Patients with known allergy to Furazidine or any other nitrofuran derivative (e.g., Nitrofurantoin) are excluded.
• Age and Life Stage: The medicine is contraindicated in infants under one month of age, and in pregnant patients who are at term (typically 38 to 42 weeks gestation).

---

Restricted or Conditional Use

• Pregnancy: Use is generally contraindicated during the first trimester. Use during the second trimester is conditional upon strict medical necessity.
• Comorbidities: Caution and close monitoring are required for patients with Diabetes Mellitus, anemia, or existing peripheral neuropathy, as these conditions may increase the risk of neurological adverse effects. Older adults also require caution due to the likelihood of reduced organ function.

This section explains the official interaction patterns documented in authoritative government regulatory sources for Furazidine. The information focuses exclusively on how co-administered substances alter drug exposure or activity, and any resulting label-based constraints.

Contraindicated and Restricted Combinations

Co-administration with alcohol (ethanol) is strictly contraindicated due to the documented risk of a disulfiram-like pharmacodynamic reaction. Combinations with certain other systemic anti-infectives, such as Chloramphenicol, are restricted or cautioned against due to the officially described risk of additive hematopoietic toxicity. Caution is also advised when co-administering with Sulfonamides due to the potential for increased undesired effects.

Exposure-Modifying Interactions

Uricosuric agents, including Probenecid and Sulfinpyrazone, inhibit the renal tubular secretion of Furazidine. This pharmacokinetic effect officially results in a reduced clearance of the drug and a consequent increase in systemic exposure. Conversely, antacids containing Magnesium trisilicate reduce the extent of absorption and require a mandatory timing separation between doses to prevent diminished systemic exposure. Official labeling notes that substances that alkalize urine reduce the antibacterial effectiveness of Furazidine.

Administration Requirement

To optimize systemic exposure, regulatory guidance requires that Furazidine be administered with food to increase the extent of its absorption.

Selective Activation by Bacterial Nitroreductases

The action of Фуразидин begins inside the pathogen cells, where it is chemically transformed by specific bacterial enzymes called nitroreductases. This unique process of reductive activation turns the inert parent molecule into highly reactive, short-lived metabolites. This selective targeting, which relies on enzymes largely absent in human cells, initiates the mechanism of action and leads to the localized generation of toxins that are predominantly active against the bacteria.

Multi-Targeted Attack on Macromolecules

Once generated, the reactive metabolites immediately unleash a simultaneous, pervasive chemical assault on the bacteria's most vital structures. They covalently bind to and damage bacterial DNA, halting replication and transcription, while also disabling ribosomal proteins and essential metabolic enzymes. This cripples the pathogen's ability to divide, synthesize proteins, and generate energy. This broad, multi-target damage is the direct mechanism that results in the bactericidal effect (pathogen cell death) and the subsequent loss of viable bacterial population.

Mechanistic Constraints and Concentration Dependence

The functional consequence of this mechanism is highly concentration-dependent. While high local concentrations ensure the rapid, definitive bactericidal effect, lower concentrations may only be sufficient to produce a bacteriostatic (growth-halting) outcome. The mechanism is also constrained or fails to execute against bacterial strains that lack the necessary nitroreductase enzymes, a key factor explaining mechanistic failure due to enzymatic lack.

Administration Guidelines: Route, Dosing, and Timing

Фуразидин (Furazidin, or its class equivalent, Nitrofurantoin) is administered via the oral route, available as tablets, capsules, or an oral suspension. The procedure for use encompasses specific dosage amounts, frequency, and specific intake conditions established for its administration.

---

Category	Standard Administration Guidelines
Route of Administration	Oral (by mouth).
Intake Condition	Must be taken with food or milk to ensure optimal systemic absorption and improve tolerance.
Dosing Frequency	Acute Treatment: Four times a day (50 mg to 100 mg conventional form) OR every 12 hours (100 mg dual-release form). Long-Term Suppression: Once daily, typically taken at bedtime.
Course Duration	The acute treatment duration is typically 7 days, or for at least 3 days after the urine is confirmed sterile. Long-term suppressive use may extend for several months.
Pediatric Dosing	Pediatric doses (for children 1 month old and older) are weight-based and administered in four divided doses per 24 hours. The medicine is contraindicated in infants under one month of age.
Administration Note	Capsules and tablets must be swallowed whole and should not be crushed or chewed.

---

This structured approach to use, with specific frequency intervals and the requirement to administer the medicine with food, is a standardized protocol. Completing the full, defined duration of therapy is an essential procedural step, regardless of symptom changes.

Overview of Research and Studies for Фуразидин

This section summarizes the available research regarding the use of Фуразидин, detailing the types of studies conducted, the outcomes measured, and where scientific evidence may be limited or ongoing. This information helps show what has been observed so far in study settings.

---

Evidence Structure for Acute Lower Urinary Tract Infections (UTIs)

Research exploring the use of Фуразидин for acute, uncomplicated lower urinary tract infections (UTIs) like cystitis and urethritis includes formal pharmacological studies, documentation in scientific literature, and recognition by international health bodies. This combination contributes to the documented evidence base. In these studies, research examined patterns related to the compound’s antimicrobial properties, exploring patterns of compound interaction relevant to bacterial processes.

In research settings, short-term trials and documented case series were used in populations experiencing acute, active UTIs due to susceptible bacteria. These studies monitored outcomes related to physical discomfort, such as changes in symptoms like pain or burning during urination (dysuria), urinary urgency, and frequency. Research also explored short-term symptom changes, tracking whether the functional imbalance associated with the acute episode evolved over the study period. Research does not determine whether an individual will respond similarly.

---

Evidence Structure for Managing and Preventing UTI Recurrence

Фуразидин was evaluated in research contexts involving fluctuating or unstable symptoms, particularly for conditions characterized by cycles of stability and flare-ups, which include recurrent UTIs. The therapeutic domain of this drug class, encompassing both treatment and prevention of these infections, is referenced in overviews from international health authorities. Research examined outcomes related to long-term management, focusing on measures like tracking the frequency of repeat symptomatic episodes. Studies monitored physiological strain or stress over defined time intervals, and research examined measures related to the maintenance of stability and functional comfort in populations prone to recurrence.

---

What Research Gaps and Uncertainties Remain

Key limitations include that comparative evidence is lacking, and direct comparison studies against other antibacterial agents are not detailed in the available documentation. Additionally, follow-up durations were limited in many studies, and long-term effects on recurrence outcomes are not fully established. Available evidence does not fully characterize how outcomes may differ in special populations, such as children, older adults, or individuals with significant underlying conditions that affect the urinary tract or immune system.

Key Studies & References

1. WHO Collaborating Centre for Drug Statistics Methodology: ATC Index (J01XE03)
2. Nitrofurantoin: MedlinePlus Drug Information

Common questions about Фуразидин (FAQ)

---

Q: What is the main reason people are prescribed Фуразидин?

According to official product information, the medicine is primarily used for managing acute, uncomplicated infections. This includes common bacterial challenges within the lower urinary tract, such as cystitis.

---

Q: How is Фуразидин different from Фурагин?

Official naming conventions indicate that Furazidin and Furagin are frequently used as chemical synonyms for the same active ingredient. Both compounds belong to the nitrofuran class of synthetic antibacterial agents.

---

Q: How long does it usually take to start noticing the effects of Фуразидин?

Research themes suggest that therapeutic concentrations in the urinary tract may be achieved within a few hours after use. Studies have examined symptomatic relief patterns that occurred within the first one to two days (24 to 48 hours) of starting the medicine.

---

Q: Why are there official warnings about certain patient groups?

Official safety documents state that warnings are necessary for specific patient groups, such as those with severe kidney impairment or a G6PD deficiency. This is because these conditions can increase the risk of the drug accumulating in the body or enhance the potential for serious side effects, including nerve damage (peripheral neuropathy).

---

Q: Is it okay to take Фуразидин with milk?

Official guidelines require that the medicine be taken with food or milk. This administration condition is described as helping to optimize the drug’s systemic absorption and may improve patient tolerance during its use.

---

Q: Does taking Фуразидин impact blood sugar levels?

Official product labeling advises that caution is required for individuals with Diabetes Mellitus. This is because the underlying condition may increase the potential for the neurological side effect known as peripheral neuropathy, which is included in the medicine's documented safety profile.

---

Q: Can a person take supplements like vitamins or minerals with Фуразидин?

Studies and official information mention that certain substances that affect the acidity of the urine may impact the drug's activity. For example, some sources note that ascorbic acid (Vitamin C) may enhance the antibacterial effect.

---

Q: Does Фуразидин treat common colds or viruses?

No, the medicine is classified as a synthetic antibacterial agent. This means its function is specifically directed at fighting bacteria and is not effective against viral illnesses, such as the common cold or flu.

---

Q: Can Фуразидин be used to prevent infections?

Research has explored the medicine’s use for more than just acute treatment. Studies examined its role in the long-term prevention or suppression of symptoms associated with recurrent urinary tract infections (UTIs).

---

Q: How long does Фуразидин stay in the body after the last use?

Information from drug studies indicates that the medicine’s terminal half-life—the time it takes for half of the substance to be eliminated—is approximately 12.0 hours. This is a measure of how the body processes the drug.

---

Q: Is there any research that summarizes the effectiveness of Фуразидин for common uses?

Yes, the official evidence summaries indicate that research has examined the drug’s properties and outcomes. This research specifically covers its use for acute lower urinary tract infections and for the management or prevention of recurrence.

---

Q: Can Фуразидин be crushed or broken for easier ingestion?

Official administration guidance states that both capsules and tablets must be swallowed whole. They should not be crushed, chewed, or opened, to maintain the integrity of the dosage form.

---

Q: Is there a generic version of Фуразидин available?

Yes, the active substance, Furazidin, is known by other names internationally due to classification standards. These include generic names such as Akritoin and F 35.

---

Q: Is it widely described as an effective treatment for its intended use?

Official documentation describes the medicine as an effective antimicrobial agent. It has a recognized and established role in managing systemic bacterial challenges, particularly those commonly encountered within the urinary system.

Storage and Disposal Requirements

Official regulatory guidelines mandate precise conditions for storing and disposing of Furazidin to ensure product stability and safety. The medication must be stored at a temperature not exceeding 25 C.

Required Protection

The product must be protected from light and protected from moisture. The medicine must be kept in the original container/packaging to preserve its validated shelf life and integrity.

Safety and Disposal

For safety, the product must be kept out of the sight and reach of children.

When disposing of unused or expired medicine, regulatory instructions require adherence to local requirements. The product must not be disposed of in wastewater or household waste to prevent environmental contamination.